Viridian Therapeutics, Inc.
Clinical trials sponsored by Viridian Therapeutics, Inc., explained in plain language.
A biopharmaceutical company developing antibody therapies for autoimmune and rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new antibody help when thyroid eye disease comes back? Results expected Apr 2027 (estimated)